We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

82 hedge funds and large institutions have $75.5M invested in Avadel Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more call options, than puts

Call options by funds: $2.87M | Put options by funds: $2.41M

15% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 20

1% more funds holding

Funds holding: 81 → 82 (+1)

7% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 15

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3.59% less ownership

Funds ownership: 60.74% → 57.15% (-3.6%)

67% less capital invested

Capital invested by funds: $230M → $75.5M (-$155M)

Holders
82
Holders Change
+1
Holders Change %
+1.23%
% of All Funds
1.38%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
16
Increased
23
Reduced
20
Closed
15
Calls
$2.87M
Puts
$2.41M
Net Calls
+$464K
Net Calls Change
-$2.46M

Top Buyers

Rank Fund Capital Flow
1
GJL
Gendell Jeffrey L
+$5.84M
2
PVI
Pura Vida Investments
New York
+$3.24M
3
BIP
Brandes Investment Partners
California
+$2.64M
4
Two Sigma Investments
Two Sigma Investments
New York
+$1.92M
5
MWM
Modera Wealth Management
New Jersey
+$1.74M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$11.4M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$9.63M
3
FLSM
Frazier Life Sciences Management
California
-$6.5M
4
ACP
Acuta Capital Partners
California
-$3.96M
5
WP
Woodline Partners
California
-$2.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
D.E. Shaw & Co
51
D.E. Shaw & Co
New York
$33K +$55.1K +13,432 New
LWAM
52
Legacy Wealth Asset Management
Minnesota
$32K – – –
XT
53
XTX Topco
Cayman Islands
$32K +$53.8K +13,093 New
SOW
54
State of Wyoming
Wyoming
$32K +$53.8K +13,103 New
CAN
55
Cetera Advisor Networks
California
$31K +$2.86K +696 +6%
Wells Fargo
56
Wells Fargo
California
$28K +$4.11K +1,000 +9%
Marshall Wace
57
Marshall Wace
United Kingdom
$27K -$337K -82,046 -88%
PI
58
PineBridge Investments
New York
$18K +$24.7K +6,009 +462%
LFG
59
Larson Financial Group
Missouri
$10K – – –
TRCT
60
Tower Research Capital (TRC)
New York
$10K +$312 +76 +2%
Zurich Cantonal Bank
61
Zurich Cantonal Bank
Switzerland
$9K – – –
BNP Paribas Financial Markets
62
BNP Paribas Financial Markets
France
$8.05K +$13.5K +3,298 New
UBS Group
63
UBS Group
Switzerland
$7K -$1.33K -323 -10%
PCH
64
Polar Capital Holdings
United Kingdom
$6.86K -$1.59M -386,662 -12%
SPIA
65
Steward Partners Investment Advisory
New York
$6K +$6.16K +1,500 +188%
Osaic Holdings
66
Osaic Holdings
Arizona
$5K – – –
LC
67
Lindbrook Capital
California
$4K +$7.39K +1,800 New
Citigroup
68
Citigroup
New York
$2K -$1.51K -368 -30%
BCV
69
Banque Cantonale Vaudoise
Switzerland
$2K – – –
HFM
70
Hartford Financial Management
Connecticut
$2K – – –
Rockefeller Capital Management
71
Rockefeller Capital Management
New York
$2K +$3.79K +924 New
APA
72
American Portfolios Advisors
New York
$1.22K +$2.05K +500 New
CG
73
Cutler Group
California
$1K -$9.46K -2,303 -77%
BWP
74
Baldwin Wealth Partners
Massachusetts
$1K – – –
CAPTRUST Financial Advisors
75
CAPTRUST Financial Advisors
North Carolina
$1K – – –
1 2
3
4

AVDL Hedge Fund Activity: Q2 2022 in Review

82 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2022, worth a combined $75.5M — down 67% from $230M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new AVDL positions and 15 closed out — a net gain of 1 holder — while 23 added to existing stakes and 20 trimmed.

The largest buyer was Gendell Jeffrey L, adding an estimated $5.84M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $11.4M sold.

  • 82 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2022, up from 81 in Q1 2022.
  • Funds reported $75.5M of Avadel Pharmaceuticals stock for Q2 2022, down 67% quarter-over-quarter.
  • 16 funds opened new Avadel Pharmaceuticals positions in Q2 2022 and 15 closed out, a net change of +1 holder.
  • The largest Avadel Pharmaceuticals buyer in Q2 2022 was Gendell Jeffrey L, an estimated $5.84M added.
  • The largest Avadel Pharmaceuticals seller in Q2 2022 was Avoro Capital Advisors, an estimated $11.4M sold.

Based on aggregated 13F filings for Q2 2022.